Completed PHASE2 INTERVENTIONAL 1-arm NCT02308137

Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)

Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS)

Sponsor: Alberta Innovates Health Solutions

Conditions Multiple Sclerosis, Secondary Progressive

Interventions Domperidone

Updated 9 times since 2017 Last updated: Feb 20, 2020 Started: Feb 28, 2015 Primary completion: Jan 3, 2020 Completion: Jan 3, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Multiple Sclerosis, Secondary Progressive and is currently completed. Alberta Innovates Health Solutions leads this study, which shows 9 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Mar 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Recruiting → Completed
May 2019 — Mar 2020 [monthly]

Recruiting PHASE2

▶ Show 4 earlier versions

Jun 2018 — May 2019 [monthly]

Recruiting PHASE2
Nov 2017 — Jun 2018 [monthly]

Recruiting PHASE2
Feb 2017 — Nov 2017 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Feb 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alberta Innovates Health Solutions
University of Calgary

Data source: University of Calgary

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Calgary, Canada